Axsome Therapeutics
AXSM
49 hedge funds and large institutions have $30.2M invested in Axsome Therapeutics in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
20% more funds holding
Funds holding: 41 → 49 (+8)
1.66% more ownership
Funds ownership: 32.21% → 33.86% (+1.7%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
27% less capital invested
Capital invested by funds: $41.6M → $30.2M (-$11.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$4.21M |
| 2 |
BlackRock
New York
|
+$2.35M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.92M |
| 4 |
NC
Nexthera Capital
New York
|
+$1.91M |
| 5 |
OPPM
Opus Point Partners Management
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.7M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.69M |
| 3 |
Morgan Stanley
New York
|
-$157K |
| 4 |
JP Morgan Chase
New York
|
-$39.9K |
| 5 |
Bank of New York Mellon
New York
|
-$39.2K |
AXSM Hedge Fund Activity: Q1 2017 in Review
49 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2017, worth a combined $30.2M — down 27% from $41.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AXSM positions and 1 closed out — a net gain of 12 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $4.21M. The largest seller was Fidelity Investments, cutting an estimated $2.7M.
- 49 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2017, up from 41 in Q4 2016.
- Funds reported $30.2M of Axsome Therapeutics stock for Q1 2017, down 27% quarter-over-quarter.
- 13 funds opened new Axsome Therapeutics positions in Q1 2017 and 1 closed out, a net change of +12 holders.
- The largest Axsome Therapeutics buyer in Q1 2017 was Royce & Associates, an estimated $4.21M added.
- The largest Axsome Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $2.7M sold.
Based on aggregated 13F filings for Q1 2017.